Nafis B. Eghrari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nafis B. Eghrari has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Chong H. Kim
MetroHealth / Case Western Reserve University School of Medicine , Cleveland, OH
2 shared publications - Amy H. Ng
The University of Texas MD Anderson Cancer Center, Department of Palliative, Rehabilitation and Integrative Medicine, Houston, Texas
1 shared publication Bryan Yavari
Arizona State University, Tempe, Arizona, USA
1 shared publicationChong H Kim
Physical Medicine and Rehabilitation, MetroHealth Medical Center, Cleveland, Ohio, USA
1 shared publication- Chong Kim
Case Western Reserve University School of Medicine
1 shared publication David C. Kaelber
Case Western Reserve University School of Medicine, Health Education Campus, 9501 Euclid Ave, Cleveland, OH, 44106; The MetroHealth System, Department of Neurological Surgery, 2500 MetroHealth Dr, Cleveland, OH, 44109
1 shared publication
Latest Publications
- 23 September 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Intraoperative Ketamine and Chronic Opioid Use After Lumbar Spine Surgery in Patients With and Without Opioid-Use Disorder: A Retrospective Database Analysis
BACKGROUND: Persistent opioid use after lumbar spine surgery (LSS) remains a major clinical concern. Ketamine is frequently included in multimodal perioperative analgesic regimens for its attenuating effects on central sensitization and its potential to reduce acute postoperative pain and opioid requirements. However, evidence regarding whether intraoperative ketamine influences longer-term outpatient postoperative opioid use is limited and mixed. We aimed to evaluate whether intraoperative ketamine administration is associated with differences in chronic postoperative opioid use after LSS, stratified by preoperative opioid exposure status. METHODS: We performed a propensity-matched retrospective cohort study using the U.S. based TriNetX Global Research Network—a database containing de-identified electronic health records—including adult patients who underwent LSS between January 2010 and December 2024. Patients were grouped based on receipt of an intraoperative ketamine and stratified by preoperative opioid status (opioid-naive or with opioid-use disorder [OUD]). Propensity score matching was used to balance demographic characteristics and relevant comorbidities. The primary outcome was the presence of outpatient opioid prescriptions at 48 hours, 6 weeks, 3, 6, and 12 months after surgery. Secondary outcomes included opioid-related adverse events and new diagnosis of OUD within 12 months of surgery. RESULTS: After matching, 53,639 opioid-naive patients and 2031 patients with OUD were analyzed. In opioid-naive patients, intraoperative ketamine exposure was associated with higher rates of outpatient opioid prescribing in the early postoperative period at 48 hours ( P < .001; risk ratio [RR] 1.23; 95% confidence interval [CI], 1.22–1.25) and 6 weeks ( P < .001; RR 1.14; 95% CI, 1.10–1.18), whereas no meaningful differences were observed at 3, 6, or 12 months. In patients with OUD, ketamine exposure was associated with higher rates of opioid prescribing only through 48 hours postoperatively. Opioid-related adverse events and new OUD diagnoses were not reduced but were, in fact, similar or more frequent among ketamine-exposed patients. CONCLUSIONS: In this large, real-world cohort, intraoperative ketamine was not associated with lower rates of chronic opioid dispensing after LSS in either opioid-naive or patients with OUD. These database findings reflect the absence of a detectable population-level opioid-sparing signal, and do not exclude dose- or protocol-dependent effects.
- 23 September 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Intraoperative Ketamine and Chronic Opioid Use After Lumbar Spine Surgery in Patients With and Without Opioid-Use Disorder: A Retrospective Database Analysis
BACKGROUND: Persistent opioid use after lumbar spine surgery (LSS) remains a major clinical concern. Ketamine is frequently included in multimodal perioperative analgesic regimens for its attenuating effects on central sensitization and its potential to reduce acute postoperative pain and opioid requirements. However, evidence regarding whether intraoperative ketamine influences longer-term outpatient postoperative opioid use is limited and mixed. We aimed to evaluate whether intraoperative ketamine administration is associated with differences in chronic postoperative opioid use after LSS, stratified by preoperative opioid exposure status. METHODS: We performed a propensity-matched retrospective cohort study using the U.S. based TriNetX Global Research Network—a database containing de-identified electronic health records—including adult patients who underwent LSS between January 2010 and December 2024. Patients were grouped based on receipt of an intraoperative ketamine and stratified by preoperative opioid status (opioid-naive or with opioid-use disorder [OUD]). Propensity score matching was used to balance demographic characteristics and relevant comorbidities. The primary outcome was the presence of outpatient opioid prescriptions at 48 hours, 6 weeks, 3, 6, and 12 months after surgery. Secondary outcomes included opioid-related adverse events and new diagnosis of OUD within 12 months of surgery. RESULTS: After matching, 53,639 opioid-naive patients and 2031 patients with OUD were analyzed. In opioid-naive patients, intraoperative ketamine exposure was associated with higher rates of outpatient opioid prescribing in the early postoperative period at 48 hours ( P < .001; risk ratio [RR] 1.23; 95% confidence interval [CI], 1.22–1.25) and 6 weeks ( P < .001; RR 1.14; 95% CI, 1.10–1.18), whereas no meaningful differences were observed at 3, 6, or 12 months. In patients with OUD, ketamine exposure was associated with higher rates of opioid prescribing only through 48 hours postoperatively. Opioid-related adverse events and new OUD diagnoses were not reduced but were, in fact, similar or more frequent among ketamine-exposed patients. CONCLUSIONS: In this large, real-world cohort, intraoperative ketamine was not associated with lower rates of chronic opioid dispensing after LSS in either opioid-naive or patients with OUD. These database findings reflect the absence of a detectable population-level opioid-sparing signal, and do not exclude dose- or protocol-dependent effects.
- 7 August 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (10) , 1158-1160
Patient-reported versus pharmacy-verified naloxone co-prescription fill rates in a chronic pain clinic: a cross-sectional discordance analysis
- 7 August 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (10) , 1158-1160
Patient-reported versus pharmacy-verified naloxone co-prescription fill rates in a chronic pain clinic: a cross-sectional discordance analysis
- Open Access
Medication prescription patterns in cancer rehabilitation physiatry outpatients: A multicenter retrospective study
Background and Objective: Previous work from this dataset found 45% prescribing frequency of any medications (35.1%, 33.5%, and 56.8% at institutions 1, 2, and 3 respectively), without significant difference between in‐person and telemedicine. The current study examines medication prescription patterns in greater depth by type of medications. Design: Multicenter retrospective study. Setting: Three academic medical centers in the United States. Participants: Patients with cancer or history of cancer. Interventions: Cancer rehabilitation physiatry outpatient visits. Main Outcome Measures: Frequency of medication types prescribed. Results: A total of 1234 unique patients underwent 3006 visits (institutions 1, 2, and 3 with 614, 1638, and 754 visits, respectively). Most frequently prescribed medication types (percentage of total encounters followed by 95% confidence interval) included opioids (14.5%; 8.1%–21.1%), membrane stabilizers (11.3.%; 5.2%–17.3%), topical agents (8.7%; 2.7%–14.7%), antidepressants (8.3%; 5%–11.8%), muscle relaxants (5%; 1.8%–8.2%), analgesics (nonsteroidal anti‐inflammatory agents or acetaminophen) (3.7%; 3.4%–4.1%), and injected agents (5%;1.7%–8.3%). Less frequent categories included bowel medications (2.4%; 0.9%–3.9%), benzodiazepines (2.6%; 0.7%–4.5%), antiemetics (1.8%; 0.3%–3.3%), antibiotics (0.7%; 0.4%–1.0%), sleep aids (1%; 0.5%–1.5%), antipsychotics (1%; 0.1–1.2%), oral corticosteroids (0.5%; 0.3%–0.7%), and cognitive medications (0.6%; 0.2%–1%). Other medications were prescribed in 9.2% (3.5%–14.9%) of encounters. Interinstitutional differences were seen for all medication categories ( p < .001), except for nonopioid analgesics ( p = .640), antibiotics ( p = .4), and corticosteroids ( p = .337). Conclusion: Treating pain appears to be a predominant but not sole focus of medication prescription in this population. Results illuminate prescribing trends seen in actual practice and may serve to inform individual cancer rehabilitation physiatrist practice, as well as to provide insight into possible directions for future research, such as focusing on frequently prescribed medications in controlled trials, and further examination of “other” medications, which were prescribed at a higher frequency than anticipated. Limitations include that factors underlying the observations could not be determined, including overall acuity; cancer type, stage, or phase; probable impact of differences in dispensation of refills depending on medication type; variability in clinically intended purposes of medications for specific cases; and possible regulatory or institution‐specific contexts.
Open AccessMedication prescription patterns in cancer rehabilitation physiatry outpatients: A multicenter retrospective study
Background and Objective: Previous work from this dataset found 45% prescribing frequency of any medications (35.1%, 33.5%, and 56.8% at institutions 1, 2, and 3 respectively), without significant difference between in‐person and telemedicine. The current study examines medication prescription patterns in greater depth by type of medications. Design: Multicenter retrospective study. Setting: Three academic medical centers in the United States. Participants: Patients with cancer or history of cancer. Interventions: Cancer rehabilitation physiatry outpatient visits. Main Outcome Measures: Frequency of medication types prescribed. Results: A total of 1234 unique patients underwent 3006 visits (institutions 1, 2, and 3 with 614, 1638, and 754 visits, respectively). Most frequently prescribed medication types (percentage of total encounters followed by 95% confidence interval) included opioids (14.5%; 8.1%–21.1%), membrane stabilizers (11.3.%; 5.2%–17.3%), topical agents (8.7%; 2.7%–14.7%), antidepressants (8.3%; 5%–11.8%), muscle relaxants (5%; 1.8%–8.2%), analgesics (nonsteroidal anti‐inflammatory agents or acetaminophen) (3.7%; 3.4%–4.1%), and injected agents (5%;1.7%–8.3%). Less frequent categories included bowel medications (2.4%; 0.9%–3.9%), benzodiazepines (2.6%; 0.7%–4.5%), antiemetics (1.8%; 0.3%–3.3%), antibiotics (0.7%; 0.4%–1.0%), sleep aids (1%; 0.5%–1.5%), antipsychotics (1%; 0.1–1.2%), oral corticosteroids (0.5%; 0.3%–0.7%), and cognitive medications (0.6%; 0.2%–1%). Other medications were prescribed in 9.2% (3.5%–14.9%) of encounters. Interinstitutional differences were seen for all medication categories ( p < .001), except for nonopioid analgesics ( p = .640), antibiotics ( p = .4), and corticosteroids ( p = .337). Conclusion: Treating pain appears to be a predominant but not sole focus of medication prescription in this population. Results illuminate prescribing trends seen in actual practice and may serve to inform individual cancer rehabilitation physiatrist practice, as well as to provide insight into possible directions for future research, such as focusing on frequently prescribed medications in controlled trials, and further examination of “other” medications, which were prescribed at a higher frequency than anticipated. Limitations include that factors underlying the observations could not be determined, including overall acuity; cancer type, stage, or phase; probable impact of differences in dispensation of refills depending on medication type; variability in clinically intended purposes of medications for specific cases; and possible regulatory or institution‐specific contexts.
- Open Access
Differential S1PR Expression and Altered Barrier, and Inflammatory Marker Levels in Human Brain Endothelial Cells Following Acute Ischemia-Reperfusion Like Injury
There are five known sphingosine-1-phosphate receptor (S1PR) types, and each type is coupled to diverse heterotrimeric G-protein subunits. S1PR type 1 (S1PR1) is highly expressed in the endothelium and receptor signaling pathways beneficially impact barrier function, thus there is a growing interest in the potential therapeutic role of S1PR1 during acute stroke injury. However, assessment of cerebrovascular S1PR1 and other S1PR expression profiles following acute ischemia-reperfusion injury have not yet been investigated. Therefore, we assessed the expression profile of human brain microvascular endothelial (HBMEC) S1PR1-5 following hypoxia plus glucose deprivation (HGD) exposure and HGD with reperfusion (HGD/R). We also investigated endothelial tight junction barrier and inflammatory mediator expression, indicative of an activated endothelial phenotype post HGD or HGD/R. Additionally, we investigated the effect of IL-1β, a downstream HGD induced inflammatory mediator, on endothelial mRNA expression of markers of function, barrier integrity, and inflammation and determined whether selective S1PR1 agonism altered mRNA expression of these genes. In terms of S1PR expression, a differential mRNA expression profile was observed revealing prominent basal endothelial expression of S1PR1-3. Following HGD, S1PR1 mRNA and protein expression increased with no observed changes in S1PR2 or S1PR3 protein levels. HGD/R increased endothelial inflammatory mediator and occludin mRNA expression with a temporal-dependent decrease in endothelial S1PR1 and claudin-5. Interestingly, we observed a positive and negative correlation between S1PR1 and S1PR2/3 with claudin-5, respectively. Selective S1PR1 agonism attenuated IL-1β induced MMP-9 mRNA and activity. In conclusion, HGD/R acutely increases endothelial cell expression of S1PR1 which presents a potential therapeutic target within the cerebrovasculature following ischemia-reperfusion injury. Additionally, HGD/R may potentially induce a phenotypic transformation within HBMECs, in which occludin expression predominates over claudin-5. NEW & NOTEWORTHY: Abstract Figure: Graphical
Open AccessDifferential S1PR Expression and Altered Barrier, and Inflammatory Marker Levels in Human Brain Endothelial Cells Following Acute Ischemia-Reperfusion Like Injury
There are five known sphingosine-1-phosphate receptor (S1PR) types, and each type is coupled to diverse heterotrimeric G-protein subunits. S1PR type 1 (S1PR1) is highly expressed in the endothelium and receptor signaling pathways beneficially impact barrier function, thus there is a growing interest in the potential therapeutic role of S1PR1 during acute stroke injury. However, assessment of cerebrovascular S1PR1 and other S1PR expression profiles following acute ischemia-reperfusion injury have not yet been investigated. Therefore, we assessed the expression profile of human brain microvascular endothelial (HBMEC) S1PR1-5 following hypoxia plus glucose deprivation (HGD) exposure and HGD with reperfusion (HGD/R). We also investigated endothelial tight junction barrier and inflammatory mediator expression, indicative of an activated endothelial phenotype post HGD or HGD/R. Additionally, we investigated the effect of IL-1β, a downstream HGD induced inflammatory mediator, on endothelial mRNA expression of markers of function, barrier integrity, and inflammation and determined whether selective S1PR1 agonism altered mRNA expression of these genes. In terms of S1PR expression, a differential mRNA expression profile was observed revealing prominent basal endothelial expression of S1PR1-3. Following HGD, S1PR1 mRNA and protein expression increased with no observed changes in S1PR2 or S1PR3 protein levels. HGD/R increased endothelial inflammatory mediator and occludin mRNA expression with a temporal-dependent decrease in endothelial S1PR1 and claudin-5. Interestingly, we observed a positive and negative correlation between S1PR1 and S1PR2/3 with claudin-5, respectively. Selective S1PR1 agonism attenuated IL-1β induced MMP-9 mRNA and activity. In conclusion, HGD/R acutely increases endothelial cell expression of S1PR1 which presents a potential therapeutic target within the cerebrovasculature following ischemia-reperfusion injury. Additionally, HGD/R may potentially induce a phenotypic transformation within HBMECs, in which occludin expression predominates over claudin-5. NEW & NOTEWORTHY: Abstract Figure: Graphical
- Top Cited PapersOpen Access
- 10 July 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (10) , 1118-1123
Risk of dementia following gabapentin prescription in chronic low back pain patients
Introduction Gabapentin is widely used to treat chronic pain, but its association with cognitive decline and dementia remains unclear. This study examined whether gabapentin prescription is associated with dementia in adults with chronic low back pain. Methods We conducted a retrospective cohort study using the TriNetX national database of de-identified patient records from 2004 to 2024. Adults diagnosed with chronic low back pain were included; those with prior gabapentin use, dementia, epilepsy, stroke, or cancer were excluded. Propensity score matching controlled for demographics, comorbidities, and pain medications. Patients were stratified by age and gabapentin prescription frequency. Primary outcomes were dementia and mild cognitive impairment. Results 26,416 adults we analyzed following propensity-score matching. Patients with six or more gabapentin prescriptions had an increased incidence of dementia (RR: 1.29; 95% CI: 1.18–1.40) and mild cognitive impairment (RR: 1.85; 95% CI: 1.63–2.10). When stratified by age, non-elderly adults (18–64) prescribed gabapentin had over twice the risk of dementia (RR: 2.10; 95% CI: 1.75–2.51) and mild cognitive impairment (RR: 2.50; 95% CI: 2.04–3.05) compared to those not prescribed gabapentin. Risk increased further with prescription frequency: patients with 12 or more prescriptions had a higher incidence of dementia (RR: 1.40; 95% CI: 1.25–1.57) and mild cognitive impairment (RR: 1.65; 95% CI: 1.42–1.91) than those prescribed gabapentin 3–11 times. Conclusions Gabapentin prescription in adults with chronic low back pain is associated with increased risk of dementia and cognitive impairment, particularly in non-elderly adults. Physicians should monitor cognitive outcomes in patients prescribed gabapentin.
- 10 July 2025
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 51 (10) , 1118-1123
Top Cited PapersOpen AccessRisk of dementia following gabapentin prescription in chronic low back pain patients
Introduction Gabapentin is widely used to treat chronic pain, but its association with cognitive decline and dementia remains unclear. This study examined whether gabapentin prescription is associated with dementia in adults with chronic low back pain. Methods We conducted a retrospective cohort study using the TriNetX national database of de-identified patient records from 2004 to 2024. Adults diagnosed with chronic low back pain were included; those with prior gabapentin use, dementia, epilepsy, stroke, or cancer were excluded. Propensity score matching controlled for demographics, comorbidities, and pain medications. Patients were stratified by age and gabapentin prescription frequency. Primary outcomes were dementia and mild cognitive impairment. Results 26,416 adults we analyzed following propensity-score matching. Patients with six or more gabapentin prescriptions had an increased incidence of dementia (RR: 1.29; 95% CI: 1.18–1.40) and mild cognitive impairment (RR: 1.85; 95% CI: 1.63–2.10). When stratified by age, non-elderly adults (18–64) prescribed gabapentin had over twice the risk of dementia (RR: 2.10; 95% CI: 1.75–2.51) and mild cognitive impairment (RR: 2.50; 95% CI: 2.04–3.05) compared to those not prescribed gabapentin. Risk increased further with prescription frequency: patients with 12 or more prescriptions had a higher incidence of dementia (RR: 1.40; 95% CI: 1.25–1.57) and mild cognitive impairment (RR: 1.65; 95% CI: 1.42–1.91) than those prescribed gabapentin 3–11 times. Conclusions Gabapentin prescription in adults with chronic low back pain is associated with increased risk of dementia and cognitive impairment, particularly in non-elderly adults. Physicians should monitor cognitive outcomes in patients prescribed gabapentin.
- Open Access
- 11 February 2025
- Published by Elsevier in World Neurosurgery
- Vol. 195, 123691
Obesity and Clinical, Radiographic, and Surgical Outcomes After Minimally Invasive Single-Level Transforaminal versus Lateral Lumbar Interbody Fusion
- 11 February 2025
- Published by Elsevier in World Neurosurgery
- Vol. 195, 123691
Open AccessObesity and Clinical, Radiographic, and Surgical Outcomes After Minimally Invasive Single-Level Transforaminal versus Lateral Lumbar Interbody Fusion
- 31 July 2024
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 104 (4) , 335-340
Impact of Body Mass Index on Opioid Prescriptions After Lumbar Spine Surgery
Objective: This study aimed to evaluate the association between body mass index and postoperative opioid use within 2 yrs after lumbar spine surgery using a national database. Methods: TriNetX, a national network of deidentified patient records, was retrospectively queried from 2003 to 2021 using International Classification of Disease 10, Current Procedural Terminology, and Veterans Affairs codes. Propensity score matching analysis was performed based on demographics, comorbidities, anxiety disorders, and mood disorders. Results: A total of 21,997 patients were included in our analysis. Patients with body mass index ≥ 30 were more likely to be prescribed opioids postoperatively (odds ratio: 1.30; 95% confidence interval: 1.18–1.42). Patients with body mass index ≥ 40 were more likely to be prescribed opioids when compared to patients with body mass index < 30 (odds ratio: 1.94; 95% confidence interval: 1.48–2.56), body mass index 30–34.9 (odds ratio: 2.06; 95% confidence interval: 1.57–2.70), body mass index 35–39.9 (odds ratio: 1.50; 95% confidence interval: 1.13–2.00), and body mass index < 40 (odds ratio: 2.06; 95% confidence interval: 1.57–2.70). The body mass index ≥ 40 group had an increased number of opioid prescriptions within 2 yrs after lumbar surgery compared to patients with body mass index 30–34.9 (P = 0.0113) and body mass index < 30 (P = 0.0018). Conclusions: Opioid prescription after lumbar spine surgery is associated with an elevated body mass index. Patients with class III obesity seem to be at the highest risk of increased opioid prescriptions after lumbar surgery. Physicians should consider the patient’s body mass index when deciding postoperative pain management.
- 31 July 2024
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 104 (4) , 335-340
Impact of Body Mass Index on Opioid Prescriptions After Lumbar Spine Surgery
Objective: This study aimed to evaluate the association between body mass index and postoperative opioid use within 2 yrs after lumbar spine surgery using a national database. Methods: TriNetX, a national network of deidentified patient records, was retrospectively queried from 2003 to 2021 using International Classification of Disease 10, Current Procedural Terminology, and Veterans Affairs codes. Propensity score matching analysis was performed based on demographics, comorbidities, anxiety disorders, and mood disorders. Results: A total of 21,997 patients were included in our analysis. Patients with body mass index ≥ 30 were more likely to be prescribed opioids postoperatively (odds ratio: 1.30; 95% confidence interval: 1.18–1.42). Patients with body mass index ≥ 40 were more likely to be prescribed opioids when compared to patients with body mass index < 30 (odds ratio: 1.94; 95% confidence interval: 1.48–2.56), body mass index 30–34.9 (odds ratio: 2.06; 95% confidence interval: 1.57–2.70), body mass index 35–39.9 (odds ratio: 1.50; 95% confidence interval: 1.13–2.00), and body mass index < 40 (odds ratio: 2.06; 95% confidence interval: 1.57–2.70). The body mass index ≥ 40 group had an increased number of opioid prescriptions within 2 yrs after lumbar surgery compared to patients with body mass index 30–34.9 (P = 0.0113) and body mass index < 30 (P = 0.0018). Conclusions: Opioid prescription after lumbar spine surgery is associated with an elevated body mass index. Patients with class III obesity seem to be at the highest risk of increased opioid prescriptions after lumbar surgery. Physicians should consider the patient’s body mass index when deciding postoperative pain management.
- 21 January 2024
- Published by Elsevier in World Neurosurgery
- Vol. 183, e936-e943
Incidence of Sacroiliac Joint Pain Following Lumbar Fractures: A Retrospective-Cohort Study
- 21 January 2024
- Published by Elsevier in World Neurosurgery
- Vol. 183, e936-e943
Incidence of Sacroiliac Joint Pain Following Lumbar Fractures: A Retrospective-Cohort Study